Drug Profile

CDR 609

Alternative Names: CDR-609

Latest Information Update: 07 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CDR-Life
Class Antibodies; Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 Jun 2025 Preclinical trials in Solid tumours in Switzerland (Parenteral) (CDR-Life pipeline; July 2025)
26 Jun 2025 CDR-Life plans IND-enabling studies for Solid tumours in the second half of 2025 (Parenteral)
22 Oct 2024 Early research in Solid tumours in Switzerland (Parenteral) before October 2024 (CDR-Life pipeline, October 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com